135 related articles for article (PubMed ID: 38214149)
1. Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors.
Yoo C; Lamarca A; Choi HJ; Vogel A; Pishvaian MJ; Goyal L; Ueno M; Märten A; Teufel M; Geng L; Morizane C
Future Oncol; 2024 Jan; ():. PubMed ID: 38214149
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series.
Yamamoto N; Tolcher A; Hafez N; Lugowska I; Ramlau R; Macarulla T; Geng J; Li J; Teufel M; Märten A; LoRusso P
Onco Targets Ther; 2024; 17():267-280. PubMed ID: 38567193
[TBL] [Abstract][Full Text] [Related]
3. Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS.
Schöffski P; Lahmar M; Lucarelli A; Maki RG
Future Oncol; 2023 Mar; 19(9):621-629. PubMed ID: 36987836
[TBL] [Abstract][Full Text] [Related]
4. The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study.
LoRusso P; Yamamoto N; Patel MR; Laurie SA; Bauer TM; Geng J; Davenport T; Teufel M; Li J; Lahmar M; Gounder MM
Cancer Discov; 2023 Aug; 13(8):1802-1813. PubMed ID: 37269344
[TBL] [Abstract][Full Text] [Related]
5. BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models.
Hao X; Bahia RK; Cseh O; Bozek DA; Blake S; Rinnenthal J; Weyer-Czernilofsky U; Rudolph D; Artee Luchman H
Neuro Oncol; 2023 May; 25(5):913-926. PubMed ID: 36521007
[TBL] [Abstract][Full Text] [Related]
6. Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial).
Zhou N; Li X; Yang Y; Tan S; Zhang S; Huang Q; Gou H
BMC Cancer; 2023 Aug; 23(1):729. PubMed ID: 37550655
[TBL] [Abstract][Full Text] [Related]
7. Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long-term survival with DeltaRex-G: A case report and literature review.
Morse MA; Chawla SP; Wong TZ; Bruckner HW; Hall FL; Gordon EM
Mol Clin Oncol; 2021 Sep; 15(3):186. PubMed ID: 34277005
[TBL] [Abstract][Full Text] [Related]
8. [The relationship and clinicopathological significance of Numb,MDM2 and p53 expression in human pancreatic cancer].
Sheng W; Dong M; Zhou J; Li X; Liu Q; Dong Q; Li F
Zhonghua Wai Ke Za Zhi; 2014 Sep; 52(9):675-81. PubMed ID: 25410780
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
10. Elevated transcript levels from the MDM2 P1 promoter and low p53 transcript levels are associated with poor prognosis in human pancreatic ductal adenocarcinoma.
Grochola LF; Taubert H; Greither T; Bhanot U; Udelnow A; Würl P
Pancreas; 2011 Mar; 40(2):265-70. PubMed ID: 21404460
[TBL] [Abstract][Full Text] [Related]
11. [Correlation between Gli1 expression and clinicopathological significance in human pancreatic cancer].
Sheng WW; Dong M; Zhou JP; Liu QF; Li X; Dong Q
Zhonghua Wai Ke Za Zhi; 2013 Oct; 51(10):916-21. PubMed ID: 24433772
[TBL] [Abstract][Full Text] [Related]
12. Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death.
Conradt L; Henrich A; Wirth M; Reichert M; Lesina M; Algül H; Schmid RM; Krämer OH; Saur D; Schneider G
Int J Cancer; 2013 May; 132(10):2248-57. PubMed ID: 23115126
[TBL] [Abstract][Full Text] [Related]
13. Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53.
Abrams SL; Akula SM; Steelman LS; Follo ML; Cocco L; Ratti S; Martelli AM; Libra M; Falzone L; Candido S; Montalto G; Cervello M; Lombardi P; McCubrey JA
Adv Biol Regul; 2022 Jan; 83():100840. PubMed ID: 34866036
[TBL] [Abstract][Full Text] [Related]
14. The Role of Circular RNAs in Pancreatic Ductal Adenocarcinoma and Biliary-Tract Cancers.
Limb C; Liu DSK; Veno MT; Rees E; Krell J; Bagwan IN; Giovannetti E; Pandha H; Strobel O; Rockall TA; Frampton AE
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33158116
[TBL] [Abstract][Full Text] [Related]
15. YY1 suppresses proliferation and migration of pancreatic ductal adenocarcinoma by regulating the CDKN3/MdM2/P53/P21 signaling pathway.
Liu D; Zhang J; Wu Y; Shi G; Yuan H; Lu Z; Zhu Q; Wu P; Lu C; Guo F; Chen J; Jiang K; Miao Y
Int J Cancer; 2018 Apr; 142(7):1392-1404. PubMed ID: 29168185
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic.
Dembla V; Somaiah N; Barata P; Hess K; Fu S; Janku F; Karp DD; Naing A; Piha-Paul SA; Subbiah V; Tsimberidou AM; Shaw K; Meric-Bernstam F; Hong DS
Oncotarget; 2018 Sep; 9(69):33232-33243. PubMed ID: 30237864
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification.
Cornillie J; Wozniak A; Li H; Gebreyohannes YK; Wellens J; Hompes D; Debiec-Rychter M; Sciot R; Schöffski P
Clin Transl Oncol; 2020 Apr; 22(4):546-554. PubMed ID: 31201607
[TBL] [Abstract][Full Text] [Related]
18. MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations.
Kim SJ; Akita M; Sung YN; Fujikura K; Lee JH; Hwang S; Yu E; Otani K; Hong SM; Zen Y
Am J Surg Pathol; 2018 Apr; 42(4):512-521. PubMed ID: 29309301
[TBL] [Abstract][Full Text] [Related]
19. Increased mdm2 expression and immunoreactivity in human pancreatic ductal adenocarcinoma.
Ebert M; Yokoyama M; Kobrin M; Friess H; Buchler M; Korc M
Int J Oncol; 1994 Dec; 5(6):1279-84. PubMed ID: 21559710
[TBL] [Abstract][Full Text] [Related]
20. Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma.
Zhang W; Vaubel RA; Oh JH; Mladek AC; Talele S; Zhang W; Waller KL; Burgenske DM; Sarkaria JN; Elmquist WF
Mol Cancer Ther; 2024 Jan; 23(1):47-55. PubMed ID: 37828724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
